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GENERATING CRISPR-CAS9 GENOME-ENGINEERED HUMAN 
EMBRYONIC STEM CELLS TO MODEL A GENETIC MECHANISM OF 
ASTHMA 
 
SEAN J. MCMANUS 
 
ABSTRACT 
 Asthma is a major public health epidemic that presents a heavy burden on those 
who suffer from the disease. Little is currently understood about the genetic signature that 
distinguishes one type of asthma from another. Recently, the single nucleotide 
polymorphism (SNP) rs968567 was found to have a high degree of association in 
asthmatic patients (Sharma et al., 2014). This particular SNP is in the promoter region of 
the FADS2 gene that synthesizes the enzyme delta-6-desaturase (D6D). D6D mediates 
the formation of pro-inflammatory factors that lead to exacerbation of asthmatic 
symptoms. We engineered a novel, customized CRISPR-Cas9 construct to induce the 
SNP rs968567 in the HUES9 human embryonic stem cell (hESC) line. Our results show 
success in generating the custom CRISPR-Cas9 construct for use in stem cells, while 
efficiency in expressing the desired mutation in our cell line is currently being optimized. 
Disease modeling in the genomic era of medicine provides an opportunity for the 
development of personalized medical treatment. Future projects aim to differentiate stem 
cell lines edited with our CRISPR-Cas9 construct to lung progenitor cells to study the 
cellular phenotype of this mutation in context of asthma pathogenesis. 
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INTRODUCTION 
Prevalence of Asthma 
Asthma has become a steadily growing epidemic, especially in the Western 
world, and is now a major public health concern for people of any gender, age, or race. 
As the scientific community continues to expand its knowledge of environmental cues 
that exacerbate asthma and common genetic links among asthmatic patients, the push to 
find a cure for asthma is greater than ever. As of now, there are no preventative medical 
measures that can be taken to stop asthma from developing in either children or adults, 
and there is no cure for asthma once an individual has developed it. 
A variety of studies have examined asthma from a public health perspective in an 
effort to quantify the burden asthma places on both the United States and global 
populations. From 2001 to 2010 the number of Americans diagnosed with asthma 
increased from 7.3% to 8.4% (25.7 million Americans total) (Akinbami et al., 2012). 
Asthma was responsible for 3,447 deaths in the United States in 2007 (Akinbami et al., 
2011). On a global scale, asthma affects approximately 300 million individuals (Croisant, 
2014). While asthma may sometimes be dismissed as a manageable burden, a 2012 study 
by the Asthma and Allergy Foundation of America determined that asthma is the number 
one cause of missed school days in the United States among school-aged children (Meng 
et al., 2012). From a financial standpoint, the Centers for Disease Control and Prevention 
(CDC) estimated that asthma accounts for $56 billion in expenses and lost productivity of 
employees (CDC 2011 as cited in Croisant, 2014). This burden is projected to grow at an 
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alarming rate as the World Health Organization predicts the number of diagnosed 
asthmatic patients will increase by 100 million by the year 2025 (World Health 
Organization 2007 as cited in Croisant, 2014). 
Childhood asthma is a subset of asthma that is particularly poorly understood. A 
variety of studies have examined a host of environmental factors that influence a child’s 
susceptibility to asthma and other atopic diseases. For instance, a study from 2011 
demonstrated that children raised on a farm had a significantly lower incidence of atopic 
disease as compared to a metropolitan cohort (Ege et al., 2011). Another study by Ferry 
et al. (2014) demonstrated that children who lived in households with carpet before the 
age of 2 were 1.4 times more likely to be diagnosed with asthma between ages 2 and 6 
than those who were eventually diagnosed with asthma but did not grow up in a 
household with carpet. Furthermore, if a child experienced a serious respiratory illness 
and grew up in a carpeted household all before the age of 2 years, then his or her risk of 
developing asthma between ages 2 and 6 increased 3.2-fold (Ferry et al., 2014).  
Asthma has also been recently linked to early childhood exposures to diesel 
exhaust particle, otherwise known as traffic pollution (Codispoti et al., 2015). Children 
who are exposed to diesel exhaust particle by 1 year of age show a positive correlation 
with developing aeroallergen sensitization by ages 2 and 3 (Codispoti et al., 2015). This 
early aeroallergen sensitization offers an interesting avenue for future research, since it 
was shown to be a risk factor for patients developing asthma at some point in their life 
(Settipane and Settipane, 2000). This finding by Settipane and Settipane in a 23-year 
follow-up with students from Brown University led them to describe the “hygiene 
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hypothesis” for developing asthma. The hypothesis says that of the two primary 
immunological pathways, T-helper 1 (Th1) and T-helper 2 (Th2), the Th1 pathway has 
slowly faded with the onset of the era of immunizations and public hygiene awareness. 
Settipane and Settipane (2000) cited the results of this study to support their hypothesis 
that the repressed Th1 pathway allows the Th2 pathway to predominate in the form of 
increased immunoglobulin E (IgE) levels, eosinophilia, atopy, and airway 
hyperresponsiveness. However, the hygiene hypothesis is not universally supported, as 
recent research points to asthma being triggered by alternative factors such as diet, 
obesity, infection, and T-cell skewing (Woodruff et al., 2009; Yang and Schwartz, 2012). 
 
Asthma Diagnosis and Symptoms 
Asthma is a chronic inflammatory respiratory disease that manifests itself in the 
form of varying degrees of bronchoconstriction, plasma excretion, and mucus secretion in 
the airway (Barnes, 1996). As a result, the heterogeneity of asthma is what makes this 
disease so difficult to diagnose and to treat adequately (Busse, 2011). A combination of 
clinical history, family history, and patient response to medication typically dictates the 
course of treatment (Busse, 2011). The most common way to diagnose childhood asthma 
is through an assessment of symptom severity, frequency of exacerbations, and degree of 
interference with normal activity (Potter, 2010). One quantitative measure that physicians 
use to diagnose asthma is through an airflow reversibility measurement (Busse, 2011). If, 
after administration of a short-acting bronchodilator, a patient demonstrates an increase 
of at least 12% in their forced expiratory volume, then the patient is diagnosed with 
 4 
 
asthma contingent upon supporting clinical symptoms (Busse, 2011). One way in which 
clinicians are able to stratify between moderate and severe asthma is on the basis of 
fractional exhaled nitric oxide (FENO) (Fitzpatrick et al., 2006). Patients with severe 
asthma were found to have 2-fold higher levels of FENO than those with moderate asthma 
(Fitzpatrick et al., 2006). 
Asthma symptoms are associated with airway hyperresponsiveness and include 
coughing, wheezing, and breathlessness (Kaufman, 2011). Lymphocytes, eosinophils, 
and mast cells that have leaked into the airway lumen are primarily responsible for 
triggering the inflammatory response underlying asthma (Barnes, 1996). In fact, the 
presence of eosinophils in the airway lumen of asthmatic patients is so predominant that 
asthma was first referred to as “chronic eosinophilic bronchitis” as far back as 1916 
(Barnes, 1996). This chronic inflammatory state, exacerbated by bouts of acute 
inflammation in response to environmental stressors, results in the shedding of airway 
epithelium, which triggers airway hyperresponsiveness (Barnes, 1996). Studies 
examining the unique microenvironment of airway epithelium in the post-shedding state 
at the level of electron microscopy have added insight into the pathophysiology of 
asthma. For instance, an earlier study revealed that shedding of airway epithelium in 
asthmatic patients creates a microenvironment conducive to production of type III and 
type V collagen, subsequently causing subepithelial fibrosis of the airway (Djukanović et 
al., 1990). 
 
Genetics of Asthma 
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 Understanding the genetic signature of asthma is a new frontier in the field of 
asthma research; challenges in this field include a lack of reproducibility across studies, 
along with hundreds of potential candidate genes (Yang and Schwartz, 2012). While 
progress is being made in terms of defining environmental triggers that predict asthma 
susceptibility at a young age, our knowledge of the genetic regulation of asthma has 
lagged behind. Asthma was first hypothesized to have a genetically inherited component 
by Dr. Bonnie Sibbald in the late 1970s. Ironically, her study in 1980 (Sibbald et al., 
1980) failed to statistically prove the presence of a common genetic defect among 
patients with either asthma or wheezy bronchitis, but the study piqued the interest of the 
scientific community with respect to a genetic link among patients with similar 
obstructive airway conditions. Subsequent twin studies have shown that asthma 
heritability is 36%-70%. This heritability is likely due to complex genetic and 
environmental interactions involving more than 100 genes with diverse impacts from 
association with immunoregulation to epithelial structure and function (Sibbald et al., 
1980). 
Recent evidence suggests that epigenetics may play a strong role in how asthma is 
inherited. For instance, a mother who has asthma is much more likely to pass down 
asthma to her children than a father who has asthma (Moffat et al., 1998). The epigenetic 
control of this parent-of-origin phenomenon was demonstrated in mice by feeding 
pregnant mice either a high- or low-methylation diet and observing the phenotype of their 
offspring (Hollingsworth et al., 2008). Hollingsworth’s group showed that mice fed with 
a high-methylation diet had progeny that demonstrated airway hyperresponsiveness, 
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airway inflammation, and increased serum IgE levels. This phenotype was reversible 
upon supplementing with the demethylating agent 5-aza-deoxycytidine. With continued 
evidence of DNA methylation affecting asthmatic symptoms, it is possible that DNA 
methylation levels from nasal or buccal samples and peripheral blood cells could be used 
as a biomarker for drug targets (Yang and Schwartz, 2012). 
 Building on the hygiene hypothesis and its predilection toward the Th2 pathway 
mediating asthmatic symptoms, a recent study managed to stratify asthmatic patients 
according to their Th2 molecular phenotype (Woodruff et al., 2009). This study classified 
patients based on levels of interleukin-13 (IL-13) and interleukin-5 (IL-5) as “Th2-high” 
and “Th2-low.” The Th2-high group showed classical symptoms of severe asthma with 
elevated serum IgE levels, high eosinophil count, high degree of airway 
hyperresponsiveness, and thickening of the reticular basement membrane. Interestingly, 
only Th2-high patients saw clinical benefit from use of inhaled corticoid steroids. Though 
asthma can have myriad genetic signatures, this study provides evidence that classifying 
patients as Th2-high or Th2-low allows a clinician to stratify patients and tailor treatment 
accordingly. Understanding the complex nature of genetic susceptibility to asthma may 
help personalize treatment based on an individual’s genetic profile.  
 
Role of Desaturase Enzymes in Asthma 
A recent genome-wide association study identified the fatty acid desaturase 2 
(FADS2) enzyme, involved in the biosynthesis of polyunsaturated fatty acids (PUFAs), 
as strongly linked to symptomatic asthma patients (Sharma et al., 2014). PUFAs are 
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categorized into the two subfamilies n-3, originating from α-linoleic acid (ALA), and n-6, 
originating from linoleic acid (LA) (Calder, 2008). ALA and LA cannot be synthesized 
by the human body, which requires them to be consumed through one’s diet (Calder, 
2008). As such, consumption of ALA and LA in the Western diet accounts for 95%-98% 
of PUFAs in the human body (Calder and Burdge, 2004). Common foods in which LA is 
found in large amounts include vegetable oils (corn, soybean, and sunflower oils) and 
products made from margarine. ALA is more commonly found in nuts, flaxseed, and 
flaxseed oil. Given the evolution of the Western diet over the past half century to feature 
foods higher in LA content, the ratio of LA:ALA in the body has significantly increased 
(Calder and Burdge, 2004). 
PUFAs are metabolized from ingested ALA and LA through the addition of 
double bonds by desaturase enzymes and the elongation of the fatty acid chain (Figure 1) 
(Calder, 2008). Ultimately, ALA is converted to docosahexaenoic acid (DHA) of the n-3 
family, and LA is metabolized to arachidonic acid (AA) of the n-6 family (Calder, 2008). 
AA is important in the pathophysiology of asthma because it is the precursor to pro-
inflammatory eicosanoids including prostaglandins, thromboxanes, and leukotrienes 
(Calder, 2008). As such, increased levels of AA in the body necessarily yield higher 
levels of pro-inflammatory eicosanoids which exacerbate asthma and other chronic 
inflammatory conditions (Martinelli et al., 2008). The two enzymes responsible for the 
synthesis of both DHA and AA are δ-5 desaturase (D5D) and δ-6 desaturase (D6D) 
(Martinelli et al., 2008). More specifically, D6D occurs upstream of D5D in the 
biosynthetic pathway of PUFAs and converts LA to γ-linoleic acid in the n-6 family and 
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ALA to stearidonic acid in the n-3 family (Calder, 2008; Martinelli et al., 2008). D5D 
later converts dihomo-γ-linoleic acid to AA in the n-6 family and eicosatetraenoic acid to 
eicosapentaenoic acid in the n-3 family (Calder, 2008; Martinelli et al., 2008). D5D is 
encoded on the fatty acid desaturase 1 (FADS1) gene, while D6D is encoded on the 
FADS2 gene. 
Many groups have shown a strong correlation between increased desaturase 
activity and inflammatory diseases. For instance, a study by Martinelli et al. (2008) 
demonstrated an increase in D6D activity among patients with coronary artery disease 
compared with healthy individuals. Martinelli’s group examined the ratio of AA:LA on 
red blood cell membranes to establish a difference in desaturase activity between the two 
cohorts. This difference was explained by the inflammatory state of the arterial wall 
during atherosclerosis (Martinelli et al., 2008). Upregulation of D6D activity has been 
linked to metabolic diseases, especially type II diabetes (Kroger et al., 2012). However, 
the identification of the particular SNPs that cause an increase in D6D activity require 
further study. One thought as to why D6D might be implicated in the pathogenesis of 
asthma is that the fatty acid composition of cell membranes could impact the 
effectiveness of glucose transporters and affect insulin sensitivity (Storlien et al., 1996).  
A different study by Lattka et al. (2010) analyzed the FADS2 gene at a transcriptional 
level and found that the SNP rs968567, a cytosine (C) to thymine (T) transition mutation 
299 base pairs upstream of the transcription start site, yielded a 2-to 3-fold increase in 
luciferase reporter gene assay. In other words, the C to T SNP resulted in a 2-to 3-fold 
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increase in expression of the FADS2 gene. Similarly, the C to T mutation resulted in 
increased DNA-binding ability of nuclear proteins (Lattka et al., 2010). 
A recent study by Sharma’s group employed expression quantitative trait locus 
(eQTL) mapping to investigate 6,706 cis-acting expression-associated variants (eSNPs) 
in cluster of differentiation 4 (CD4+) lymphocytes in hopes of pinpointing genetic 
variants associated with asthma (Sharma et al., 2014). This study clearly showed 
associations with asthma for eSNPs in the FADS2 gene. The C allele on chromosome 
11q demonstrated an increased risk of asthma in this study. Of the two eSNPs found to be 
of statistically significant importance on the FADS2 gene, the SNP rs968567 in the 
conserved promoter region explained 30% of the variance of expression of this gene, 
while SNP rs174611 explained 11% of the variance. Further evidence was found to 
support FADS2 gene expression as an important asthmatic marker by demonstrating 
increased FADS2 mRNA expression in CD4+ lymphocytes in the study. Additionally, the 
eSNPs rs968567 and rs174611 were found in segments of DNA showing histone 
modifications conducive to enhancer activity (Sharma et al., 2014). 
 
CRISPR-Cas9 Genome Engineering 
The implementation of the clustered regularly interspaced short palindromic 
repeats-CRISPR-associated protein 9 (CRISPR-Cas9) genome editing system in 
mammalian cells has made a remarkable impact on how scientists are able to precisely 
target sequences of interest in the genome. CRISPRs were first found in E. coli by 
Ishino’s group in 1987 as part of the bacterial adaptive immune system (Garneau et al., 
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2010; Sander and Joung, 2014). In the last decade scientists began to realize the potential 
for harnessing this bacterial defense strategy for use in mammalian cells to edit the 
genome. The CRISPR-Cas9 system improves upon previous genome editing techniques, 
such as zinc finger nucleases and transcription activator-like effector nucleases, because 
it demonstrates significantly fewer off-target mutations, and it only requires the 
engineering of a short guide RNA (sgRNA), instead of entire proteins, which can be 
costly and inefficient (Jiang et al., 2013). 
The CRISPR-Cas9 system is comprised of CRISPR sequences, a sgRNA, and a 
Cas9 nuclease used to induce a DNA double-stranded break at the point of interest (Cong 
et al., 2013). Jinek’s group showed that the Cas9 nuclease is made up of a RuvC domain 
which is responsible for cleaving the non-target strand and an HNH domain which is the 
primary domain responsible for cleaving the DNA (Jinek et al., 2014). When the 
CRISPR-Cas9 system is used the DNA repairs itself by either nonhomologous end-
joining (NHEJ) or homology-directed repair (HDR) (Mali et al., 2013). When either the 
RuvC or HNH domain is inactivated, the ratio of repair by NHEJ to HDR increases while 
toxicity decreases (Mali et al., 2013). The sgRNA that is part of this CRISPR-Cas9 
system is approximately 20 base pairs and is chosen so that it binds by means of 
nucleotide base pairing with the DNA sequence of interest. Pattanayak’s group showed 
that the shorter, less active sgRNAs are more specific and less tolerant of mutations than 
the longer sgRNAs (Pattanayak et al., 2013). The protospacer adjacent motif (PAM) 
sequence of DNA is just downstream of the target sequence and is important for binding 
of the Cas9 nuclease (Cong et al., 2013). 
 11 
 
The CRISPR-Cas9 system has wide-ranging impacts from designing phage-
resistant bacteria used in industrial fermentation processes to administering functional 
genes to patients in a clinical setting (Hsu et al., 2014). This new technique is also very 
useful for genetic screening in that it now allows one to inactivate both copies of a gene 
in diploid mammalian cells which was previously very difficult to achieve (Wang et al., 
2014). Disease modeling is another application for which the CRISPR-Cas9 system 
shows tremendous potential because researchers can insert or delete certain genes with 
ease to study treatments for specific diseases. For instance, Lombardo’s group showed 
that in lymphocytes if you are able to inactivate the cysteine-cysteine chemokine receptor 
5 (CCR5) receptor by NHEJ, then it may be a potential method for avoiding HIV 
infection (Lombardo et al., 2007). A group at MIT was recently able to utilize the 
CRISPR-Cas9 system to correct in mice a mutation in fumarylacetoacetate hydrolase, an 
enzyme playing a role in the catabolism of tyrosine that leads to hereditary tyrosinemia 
(Yin et al., 2014). Another study demonstrated the ability to rescue mice progeny from 
cataracts caused by a one base pair deletion in the critical Crygc gene by injecting 
zygotes with a CRISPR-Cas9 construct and correcting the mutation (Wu et al., 2013). 
With respect to the research presented in the following pages, the CRISPR-Cas9 system 
was used to design a custom construct to induce the SNP rs968567 so we could model in 
human embryonic stem cells (hESCs) the C to T mutation in the conserved FADS2 
promoter region which upregulates desaturase activity and is thought to be present in 
genetically inherited forms of asthma. 
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Specific Aims/Objectives 
    The first objective of this study was to design a customized CRISPR-Cas9 
construct that could be successfully inserted into a hESC line of interest. The CRISPR-
Cas9 construct provides a way to induce a double-stranded break in the DNA at a precise 
location (Figure 2). This break then allows the cell to repair by either HDR or NHEJ. The 
second objective was to design a single-stranded oligodeoxynucleotide (ssODN) to direct 
DNA repair after cleavage by our CRISPR-Cas9 construct such that a C to T transition 
mutation occurs in the highly conserved FADS2 promoter region 299 base pairs upstream 
from the transcription start site. This mutation is known as the SNP rs968567 and has 
been shown to have a strong correlation with inheritance of asthma. The third objective 
of this research was to successfully generate a cell line with the mutation of interest in a 
hESC line. This cell line could then be utilized to study the effect of this FADS2 
mutation on lung development through differentiation of the hESCs to lung progenitor 
cells. The beauty of disease modeling in embryonic stem cells instead of mature lung 
cells is that one can take a stem cell line with this FADS2 polymorphism and direct it to 
become almost any other cell type in the human body. This allows one to study the 
effects of this mutation on a variety of other organ systems. 
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METHODS 
CRISPR-Cas9 Customized Construct 
In order to induce the targeted SNP into our HUES9 hESC line, the CRISPR-Cas9 
construct was engineered using the protocol described by Ran et al. (2013). This SNP 
results in a C to T transition mutation. At this locus 299 base pairs upstream of the 
transcription start site in the FADS2 promoter region, 92.75% of the population has a 
cytosine base pair, and the remaining 7.25% has the disease-associated thymine base pair. 
The sgRNA sequence of the CRISPR construct was chosen so that it hybridized with a 20 
base pair region spanning the SNP of interest and meeting the qualification of proximity 
to a PAM sequence (Figure 3). This sequence was selected using the CRISPR design tool 
(http://crispr.mit.edu) for its proximity to the target site and limited predicted off-target 
effects. This allowed the Cas9 nuclease to cleave at the desired base pair. The ssODN 
was designed to span the target region with homology arms of approximately 60 base 
pairs on either side. The ssODN differed from the target sequence by one base pair (the 
SNP of interest). CRISPR plasmid pSpCas9(BB)-2A-GFP (PX458) from the Feng Zhang 
lab was obtained through Addgene (plasmid #48138; Cambridge, MA). The sgRNA 
sequence was cloned into the CRISPR vector which also carried Cas9 and green 
fluorescent protein (GFP) for positive selection. Successful cloning was confirmed by 
Sanger sequencing performed by GeneWiz (Cambridge, MA).  The plasmid co-
expressing the sgRNA, Cas9 nuclease, and GFP was amplified in lysogeny broth (LB)-
ampicillin culture medium. Plasmid DNA was then purified in preparation for delivery of 
the CRISPR-Cas9 construct into the HUES9 hESC line by nucleofection. 
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CRISPR-Cas9 Delivery by Nucleofection 
 
HUES9 hESCs were cultured for nucleofection in three wells of a 6-well plate on 
Matrigel (Corning, Tewksbury, MA) in 2 mL Essential 8 Basal Medium (E8) and E8 
Supplement (Life Technologies, Grand Island, NY). Medium was replaced every 24 
hours in each well. Cells were grown to about 80% confluency before carrying out the 
following Amaxa nucleofection procedure (Lonza, Walkersville, MD). A quantity of 10 
µM of Rho-associated protein kinase (ROCK) inhibitor (Y-27632) was added to the 
medium in HUES9 wells 3 hours before electroporation. Cells were dissociated from the 
substrate using Accutase (StemCell Technologies, Vancouver, Canada), which ensured 
single-cell dissociation. Dissociated cells were counted under the microscope, and 8 x 105 
cells were resuspended in 100 µL of Nucleofector Solution 1. A combination of 2.5 µg of 
plasmid DNA and 2.5 µg of ssODN repair template P was added to the 100 µL cell 
suspension. The 100 µL solution was transferred to an Amaxa nucleofector cuvette and 
allowed to run through the B-016 program in the nucleofector (settings are proprietary 
technology). After nucleofection, 0.5 mL E8 was added to each of the three nucleofector 
cuvettes and the resulting solution was evenly plated in three wells of a 6-well plate. The 
other three wells of the 6-well plate were seeded with HUES9 cells without nucleofection 
to serve as a negative control for future fluorescence-activated cell sorting (FACS). 
Twenty-four hours after seeding nucleofected cells, the medium was replaced with E8 
medium with no ROCK inhibitor. 
 
 15 
 
Fluorescence-Activated Cell Sorting (FACS) of GFP+ HUES9 Cells 
  Forty-eight hours after nucleofection, fluorescence microscopy was used to 
confirm the transfection of the CRISPR-Cas9 construct into the cells by presence of a 
green signal. After visual confirmation, cells were dissociated from each well using 
Accutase and combined into one 15 mL centrifuge tube. FACS was carried out courtesy 
of the on-site Brigham and Women’s Hospital FACS Core using their standard 
procedures. Post-FACS cells (GFP+) were determined to have a concentration of 1.5 x 
104 cells/mL. In a 6-well plate, 300 µL of this cell suspension was plated in each of three 
wells and 1000 µL was plated in one well. Post-FACS medium made up of E8, 10 µM 
ROCK inhibitor, and 1X penicillin/streptomycin was used to culture the cells for the first 
two days post-plating. Medium was changed every 24 hours, and on day three the 
medium was switched to standard E8 medium.  
 
Surveyor Mutation Detection Kit  
The Surveyor Mutation Detection Kit (Integrated DNA Technologies, Coralville, 
IA) was used to scan the heteroduplex DNA created by our engineered CRISPR-Cas9 
construct and to cleave the DNA using the Surveyor nuclease on the 3' end of both 
known and unknown polymorphisms. We used the HotStarTaq Plus Master Mix Kit 
(Qiagen, Limburg, Netherlands) to amplify reference DNA from wild type HUES9 cells 
as well as DNA collected from a mixed cell population after nucleofection with CRISPR 
construct both before and after FACS. The polymerase chain reaction (PCR) products 
hybridized to form homo- and hetero-duplexes by running the program listed in Table 1 
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in the C1000 Thermal Cycler (Bio-Rad, Waltham, MA). Once the heteroduplexes 
formed, PCR products were treated with the Surveyor nuclease. The reference DNA was 
also treated with the Surveyor nuclease to serve as a negative control. After Surveyor 
nuclease, Surveyor enhancer, and 0.15 M MgCl2 were added, the solution was allowed to 
incubate at 42 °C for 60 minutes. The kit “stop solution” was added to terminate the 
reaction. A 2% agarose gel was then used to analyze the DNA fragments (reference 
without nuclease treatment, reference with nuclease treatment, mixed cell DNA prior to 
FACS, and mixed cell DNA post-FACS) to determine if Surveyor nuclease cut the 636 
base pair DNA fragment into a 126 base pair fragment and a 510 base pair fragment. 
 
Cell Culture Subcultivation 
After the GFP+ sorted cells were plated, they were cultured until colonies were 
large enough to passage, but still isolated representing a colony generated from a single 
cell. Seventy-two colonies were picked and transferred to individual wells on three 24-
well plates. Each well was given a unique indexing code (72 unique wells total). These 
cells were cultured in 0.5 mL of E8 per well. When each well was confluent they were 
split 1:2, with one plate serving as a maintenance plate and the other as a duplicate. These 
cells were maintained until DNA could be collected from each line and a stock was 
frozen back. 
 
2.6 DNA Isolation 
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After the second passage onto 24-well Matrigel plates, confluent wells were 
selected for DNA isolation. DNA isolation was carried out according to the procedure 
outlined by Laird et al. (1991). A 0.5 mL quantity of lysis buffer (prepared according to 
protocol) was added to each well ready for harvesting and allowed to incubate in the 
Excella E24 Incubator Shaker series (New Brunswick, Edison, NJ) series set at 37 °C and 
180 rotations per minute (rpm) for 2.5 hours. During incubation, 1.5 mL sterile microfuge 
tubes were labeled with a corresponding well identification code, and 200 µL DNA 
recovery solution (prepared according to protocol) was added to each microfuge tube. 
After incubation, 500 µL isopropanol was added to each well, two wells at a time, and the 
plate was shaken vigorously to initiate DNA precipitation. A 2.5 µL pipette tip was used 
to gather DNA strands and transfer them to the respective microfuge tube. After all DNA 
had been transferred to microfuge tubes, five or six tubes were packed into 50 mL conical 
tubes and taped vertically to the inside of the Hybaid Shake ‘n’ Stack hybridization oven 
(Thermo Scientific, Waltham, MA). The samples were allowed to spin for 24-48 hours at 
37 °C and were then tested for DNA concentration. Samples with at least 30.0 ng/µL 
DNA were amplified using the HotStarTaq Master Mix Plus PCR Kit and sent off for 
sequencing to test for presence of desired FADS2 promoter mutation. 
After DNA isolation and amplification, it was necessary to run a purification 
procedure that prepared the amplified DNA product for Sanger sequencing. The PCR 
purification procedure was followed according to the QIAquick Spin Kit (Qiagen, 
Limburg, Netherlands) by first adding 250 µL of supplied PBI buffer to 50 µL of our 
PCR product. This solution was transferred to a QIAquick spin column and centrifuged 
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for 60 seconds at 17,900 rpm. The “flow-through” was discarded, and 750 µL of supplied 
PE buffer was added to the QIAquick spin column. This was again centrifuged for 60 
seconds at 17,900 rpm. The “flow-through” was discarded, and the column was 
centrifuged one last time for 60 seconds at 17,900 rpm to ensure the removal of any 
excess ethanol. The QIAquick spin column was placed in a sterile 1.5 mL microfuge 
tube, and 50 µL of supplied EB buffer was added directly to the membrane of the 
column. The column was allowed to sit for 60 seconds, and then it was centrifuged for 60 
seconds at 17,900 rpm. DNA concentration of the now-purified PCR product was 
measured on the NanoDrop 2000 spectrophotometer (ThermoScientific, Waltham, MA) 
and sent to GeneWiz for Sanger sequencing. 
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RESULTS 
Engineering CRISPR-Cas9 Construct to Induce SNP rs968567 in FADS2 Gene 
Based on the recent study by Sharma et al. (2014) that demonstrated a strong 
association between a mutation in the FADS2 promoter region and asthmatic patients, 
our aim was to induce this polymorphism and model the phenotype in hESCs. The 
mutation of interest was SNP rs968567 which results in a C to T transition mutation in 
the promoter region of the FADS2 gene 299 base pairs upstream from the transcription 
start site. This SNP accounts for 30% of the variance in FADS2 expression, making it an 
intriguing candidate to study for its effects on diseases associated with chronic 
inflammation (Sharma et al., 2014). We utilized the new CRISPR-Cas9 RNA-guided 
genome engineering tool to introduce this SNP into our HUES9 hESCs (Figure 2). We 
designed a sgRNA sequence that was complementary to the 20 base pairs spanning the 
desired mutation (Figure 3). This sgRNA served as a guide to direct the Cas9 nuclease to 
create a double-stranded break in the FADS2 promoter region. A DNA repair template 
was added to encourage DNA repair by HDR with maximum efficiency and minimal off-
target mutations. A FACS assay confirmed the presence of our CRISPR-Cas9 construct 
in HUES9 hESCs and also allowed positive selection of transfected cells (Figure 4). 
GFP+ cells indicated proper introduction of the CRISPR-Cas9 construct because the 
plasmid that was nucleofected contained the CRISPR-Cas9 construct and GFP. The GFP+ 
cells were used to run a Surveyor Mutation Detection assay to see if the recently 
introduced CRISPR-Cas9 construct was functioning properly by cutting the DNA at the 
desired locus. In Figure 5, a 2% agarose gel was run with control HUES9 cells, control 
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HUES9 cells with the Surveyor nuclease added, HUES9 cells nucleofected with 
CRISPR-Cas9 construct before FACS, and HUES9 cells with the CRISPR-Cas9 after 
FACS. Comparison of the GFP+ HUES9 cells post-FACS (lane 6) with the control 
HUES9 cells (lane 3) clearly indicated that the initial 636 base pair PCR product was 
successfully cut into a 126 base pair fragment and a 510 base pair fragment. The band in 
lane 3 would not be expected to be cut since there was no digestion by any nucleases. 
 
Detection of Insertions or Deletions (Indels) in Sequenced DNA of HUES9 Cells with 
CRISPR-Cas9 Custom Construct 
After confirming the transfection of our custom-engineered CRISPR-Cas9 
construct into the HUES9 hESC line, we aimed to see if the desired SNP rs968567 was 
now present in the cells. We estimated that 20% of the HUES9 cell line would carry a 
mutation (indel or specific mutation) based on the Surveyor assay, which led us to select 
72 colonies to plate on three separate 24-well plates. Based on our calculations, 
approximately 14 colonies would express a mutation, and we could then differentiate 
those colonies to lung progenitor cells to study the phenotype of the induced mutation 
during lung development. Figure 6 shows the cell culture subcultivation and 
identification process we employed to propagate the HUES9 cell line. After isolating 
DNA from sufficiently confluent wells and sending the DNA for Sanger sequencing at 
GeneWiz, we began tracking which, if any, colonies expressed the desired polymorphism 
(Figure 7). To date, we have sequenced 39 colonies and none of the sequenced data 
showed SNP rs968567 (Figure 7). Twenty colonies (51.3%) showed the presence of a 
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heterozygous indel, 16 colonies (41%) showed the presence of a homozygous indel, and 
3 colonies (7.7%) did not have any indels present. Of the 20 homozygous indels, eight 
colonies expressed a homozygous mutation with an adenine base pair inserted in the 
same locus on the DNA strand. The insertion of this adenine was thought to be a 
stochastic occurrence and not the result of an inter-allelic gene conversion event during 
the DNA repair process. 
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DISCUSSION 
Interpretation of Sanger Sequencing Results 
Disease modeling offers a powerful tool for manipulating variables of interest and 
studying their effects on disease phenotypes. Genome-wide association studies (GWAS) 
provide a way to examine a host of genetic variants to see if they have a statistically 
significant correlation with a disease of interest. In the case of our study, we leveraged 
the recent evidence of the SNP rs968567 in the FADS2 promoter region having a high 
degree of association with asthma as shown in an eQTL assay (Sharma et al., 2014). We 
were able to generate a novel, customized CRISPR-Cas9 construct that was designed to 
induce a C to T mutation 299 base pairs upstream of the promoter in the FADS2 gene. 
However, at the time of submission we were unsuccessful in detecting this mutation in 
any of our sequenced DNA. 
Analysis of the sequencing data from each round of sequencing showed that in the 
instances of a homozygous mutation, 40% of the homozygous mutations occurred with 
the insertion of an adenine in a position upstream of the desired mutation. The insertion 
occurred in the same locus upstream in all of these cases. Recent literature suggests a 
phenomenon called “interallelic gene conversion” that may occur when a double-stranded 
break is induced, such as in the CRISPR-Cas9 system (Yoshimi et al., 2013). This event 
takes place when the DNA does not use the supplied ssODN as its repair template, but 
rather uses a segment of DNA from an adjacent chromosome as its source for DNA 
repair. This can often be confirmed by matching the sequence of the unknown insertion 
with the same exact sequence somewhere on a homologous chromosome. 
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We do not believe that inter-allelic gene conversion was responsible for the one 
base pair insertion. Rather, we hypothesize that DNA repair occurred by NHEJ with 
errors as opposed to the desired HDR method. The insertion of the adenine occurred at 
the cutting point for the Cas9 nuclease, which makes this region of DNA particularly 
susceptible to indels. The inter-allelic gene conversion phenomenon most likely explains 
the homozygous nature of our observed indels. Given the 40% occurrence of the adenine 
insertion, we sequenced the rest of the genome to determine if there was an identical 
sequence of DNA with the adenine insertion that could explain its repeated occurrence. If 
an identical sequence appeared elsewhere in the genome, then this would strengthen the 
argument for inter-allelic gene conversion being responsible for the adenine insertion. We 
found no identical sequence in the rest of the genome with the insertion of an adenine, 
which leads us to conclude that the insertion of an adenine in these homozygous indels is 
indeed a random occurrence. 
 To rule out the possibility that our repair template was not made correctly, we 
sequenced the ssODN and found that it matched exactly what we had designed. A 
possible way to remedy this dilemma would be to increase the concentration of ssODN 
that is transfected into the HUES9 cells. If the ssODN repair template is not available in a 
high enough quantity for the cell to utilize during its DNA repair process, then it is 
natural to assume that the cell will defer to repair by NHEJ or use a nearby sequence of 
DNA for the repair process. One may increase the amount of ssODN by either increasing 
the concentration of available ssODN or improving the efficiency of nucleofection. The 
repair template may simply not have been nucleofected into the cells along with the 
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plasmid containing the CRISPR-Cas9 construct. However, improving the nucleofection 
efficiency may prove to be difficult because of proprietary technology that prohibits the 
customer from knowing the exact settings for each program. It is quite possible that the 
Cas9 nuclease degraded the ssODN along with the targeted DNA strand. The ssODN is 
essentially identical to the targeted DNA strand with the exception of a C to T mutation. 
This close resemblance could lead to the Cas9 nuclease degrading the ssODN instead of 
the DNA strand, which would abort the HDR process and transition to NHEJ. 
The FACS process may also be a rate-limiting-step in terms of our lack of 
efficiency in finding the desired mutation in this experiment. It is possible that choosing a 
greater proportion of GFP+ cells and seeding more colonies (perhaps an extra 24 wells) 
would have resulted in a positive finding in our sequencing data. However, it may be 
beneficial to seek improvements and adjustments elsewhere in the process instead of 
simply looking at more cells as the solution. The FACS efficiency could possibly be 
improved next time, particularly since the cell suspension was allowed to sit for 1 hour 
longer than expected as a result of a long wait time at the FACS Core facilities. This 
prolonged time in a suboptimal environment for stem cells could cause an increase in 
apoptosis which would lessen the amount of GFP+ cells in the post-FACS analysis. 
 
Directed Differentiation of hESCs to Nkx 2.1+ Lung Progenitor Cells 
This project was designed so that it has a broad range of applications once the 
fundamental tools have been established. In addition to her enormous amount of support 
and scientific guidance throughout this project, Dr. Jeanne M. Carroll is also working on 
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a parallel project to establish a differentiation protocol to make Nkx 2.1+ lung progenitor 
cells from hESCs. The establishment of a highly efficient lung progenitor differentiation 
protocol will enable us to take colonies of hESCs that have the desired FADS2 mutation 
and differentiate them into Nkx 2.1+ lung progenitor cells. This would permit us to 
carefully study the phenotype of stem cells with this mutation during the differentiation 
process and make comparisons with wild type stem cells following the same process. A 
future study like this would likely lead to a better understanding of the pathophysiology 
of asthma and perhaps a more focused scope of important candidate genes involved in 
various types of asthma. Moreover, our goal of establishing the FADS2 mutation in 
hESCs would allow us to differentiate into a variety of other lineages including liver, 
heart, kidney, and neuronal cells. For example, as more is learned about the impact of this 
mutation, it may be useful to pivot from lung progenitor cells and study the FADS2 
mutation in liver cells. Using the CRISPR-Cas9 customized construct to establish our 
desired mutation in hESCs gives us the flexibility to conduct this type of study in the 
future. 
A differentiation protocol is a difficult task to perfect, especially since an 
extremely high efficiency (typically above 90%) is needed in order to consider the 
protocol a success. Results from a disease modeling study in a cell population in which 
only 50% of the cells have differentiated into the lineage of interest, compared with a 
protocol that yields 90% of lineage-specific cells, will understandably be taken with a 
healthy degree of skepticism. Dr. Carroll’s lung differentiation project is based on 
optimizing the protocol published by Huang et al. (2015) in which they differentiated 
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embryoid bodies into Nkx 2.1+ lung progenitor cells. The process takes 25-50 days to 
generate mature lung and airway epithelial cells by going through a series of four steps. 
In step 1, the hESCs must be differentiated from their pluripotent state into definitive 
endoderm as confirmed by expression of the two genes known as SRY (sex-determining 
region Y)-box 17 (Sox17) and forkhead box A2 (FoxA2) (Figure 8). Next, in step 2, the 
definitve endoderm must be anteriorized to form anterior foregut endoderm (Figure 9). 
The timing is crucial because there is only a small window of time in which the cells are 
optimized for anterior foregut formation before proceeding onto posterior foregut 
endoderm. Once the anterior foregut endoderm cells have properly expanded, it is time 
for lung progenitor induction (step 3) followed by lung/airway epithelial maturation (step 
4). This incredibly precise four-step process is mediated by manipulating media 
components on certain days of the differentiation process in order to turn on and off 
specific genes that are instrumental in forming either definitive endoderm, anterior 
foregut endoderm, lung progenitor cells, or mature lung/airway epithelial cells. 
Overall, this study resulted in the successful engineering of a novel CRISPR-Cas9 
construct designed to induce the SNP rs968567 into hESCs in an effort to model asthma 
in lung progenitor cells. The CRISPR-Cas9 construct will also allow us and others to 
study the FADS2 mutation in a variety of different cell lineages. Future efforts will 
revolve around improving the nucleofection and HDR efficiency in order to generate a 
higher yield of stem cells with our desired mutation present.  
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Table 1.  Surveyor Mutation Detection Kit Hybridization Schedule 
 
Temperature Time Temperature Ramp 
95 °C 10 min  
95 °C → 85 °C  -2.0 °C/s 
85° C 1 min  
85 °C → 75 °C  -0.3 °C/s 
75 °C 1 min  
75 °C → 65 °C  -0.3 °C/s 
65 °C 1 min  
65 °C → 55 °C  -0.3 °C/s 
55 °C 1 min  
55 °C → 45 °C  -0.3 °C/s 
45 °C 1 min  
45 °C → 35 °C  -0.3 °C/s 
35 °C 1 min  
35 °C → 25 °C  -0.3 °C/s 
25 °C 1 min  
4 °C HOLD  
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Figure 1. Metabolic pathway of n-3 and n-6 PUFAs. Flowchart shows the precursors, 
intermediates, and end products in PUFA metabolism. The enzyme D6D, encoded by 
FADS2, converts LA to γ-LA and has been shown to be associated with asthma. An 
increase in D6D activity leads to an increase in AA and subsequent increase in pro-
inflammatory eicosanoids. (AA = arachidonic acid; D6D = δ-6 desaturase; FADS2 = 
fatty acid desaturase 2; LA = linoleic acid; PUFAs = polyunsaturated fatty acids.) 
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Figure 2. CRISPR-Cas9 mechanism of action. Diagram shows the theory behind how 
the CRISPR-Cas9 system works to induce DNA double-stranded breaks. The 
sgRNA/Cas9 complex binds by Watson-Crick base pairing at the desired location near 
the PAM sequence. The Cas9 nuclease recognizes the PAM sequence and binds to the 
DNA where it induces a double-stranded break at the desired base pair. DNA is then 
repaired by HDR with a supplied repair template so that the DNA strand re-forms with 
the new insertion or deletion. Adapted from Ran et al. (2013). (Cas9 = CRISPR-
associated protein 9; CRISPR = clustered regularly interspaced short palindromic repeat; 
DNA = deoxyribonucleic acid; HDR = homology-directed repair; PAM = protospacer 
adjacent motif; sgRNA = small guide RNA.) 
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Sense Strand 5’        GTGGAAACTCGGGCGGCGGGGAACGCGGGAGGATGTGG 
 
Antisense Strand 3’  CACCTTTGAGCCCGCCGCCCCTTGCGCCCTCCTACTCC 
 
Sense Strand 5’        AACCCGAGGCGGGGGGAGCCGGAGGGGCGGGCAGAGGA 
 
Antisense Strand 3’ TTGGGCTCCGCCCCCCTCGGCCTCCCCGCCCGTCTCCT 
 
Sense Strand 5’        GGTGTCGAGGCCCTGAGCTCCCGGGGAGTTTTTACTGGA 
 
Antisense Strand 3’ CCACAGCTCCGGGACTCGAGGGCCCCTCAAAAATGACCT 
 
Sense Strand 5’        GGCAAAAGTCCATAGCGGGAGGGCTGAGGGAGGGGCGGA 
 
Antisense Strand 3’  CCGTTTTCAGGTATCGCCCTCCCGACTCCCTCCCCGCCT 
 
Sense Strand 5’         GGAAGGGGACCGCTTGGGGGCACTGGGAAGCCAGGGAT 
 
Antisense Strand 3’   CCTTCCCCTGGCGAACCCCCGTGACCCTTCGGTCCCTA 
 
Sense Strand 5’         CCTCCGCC 
 
Antisense Strand 3’  GGAGGCGG 
 
 
 
Red = PAM sequence 
Blue = sgRNA 
Green = Target allele for mutation 
 
Figure 3. CRISPR-Cas9 customized construct and FADS2 gene sequence. Sequence 
shows a portion of the FADS2 gene in the promoter region that contains the PAM 
sequence, where our sgRNA will bind, and the specific base pair in which we are aiming 
to induce a C to T transition mutation. (Cas9 = CRISPR-associated protein 9; CRISPR = 
clustered regularly interspaced short palindromic repeat; FADS2 = fatty acid desaturase 
2; PAM = protospacer adjacent motif; sgRNA = small guide RNA.) 
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Figure 4. FACS results for HUES9 cells post-nucleofection. Plot in bottom left (PE-A 
vs. FITC-A) shows the cohort of GFP+ cells chosen for cell culture subcultivation and 
DNA sequencing to confirm if desired SNP was properly induced. Cells that strongly 
express GFP in the FACS assay provide confirmation that nucleofection introduced the 
customized CRISPR-Cas9 construct into the HUES9 cell line. (Cas9 = CRISPR-
associated protein 9; CRISPR = clustered regularly interspaced short palindromic repeat; 
DNA = deoxyribonucleic acid; FACS = fluorescence-activated cell sorting; FITC-A = 
fluorescein isothiocyanate - area; FSC-A = forward-scattered light - area; FSC-H = 
forward-scattered light - height; GFP = green fluorescent protein; P1-P5 = events 1-5; 
PE-A = phycoerythrin - area; SNP = single nucleotide polymorphism; SSC-A = side-
scattered light - area.) 
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     Well 1    Well 2      Well 3       Well 4     Well 5     Well 6     Well 7                  
 
 
Figure 5. Surveyor mutation detection gel. A 2% agarose gel was run to determine if 
the custom-engineered CRISPR-Cas9 construct was properly introduced into HUES9 
cells by nucleofection. Well 1: DNA ladder; Well 2: No template control (no DNA 
should be present); Well 3: HUES9 cells and no digestion with supplied Surveyor 
nuclease; Well 4: HUES9 cells with no CRISPR-Cas9 construct and digestion with 
supplied Surveyor nuclease; Well 5: HUES9 cells before FACS with CRISPR-Cas9 
construct added by nucleofection; Well 6: HUES9 cells that were GFP+ after FACS with 
CRISPR-Cas9 construct added; Well 7: Same DNA ladder as Well 1. (Cas9 = CRISPR-
associated protein 9; CRISPR = clustered regularly interspaced short palindromic repeat; 
DNA = deoxyribonucleic acid; FACS = fluorescence-activated cell sorting.) 
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Figure 6. Cell culture flow chart. Flow chart depicts the tracking scheme of each 
selected HUES9 colony through subcultivation. Cells were harvested for DNA isolation 
and subsequent Sanger sequencing once each well reached about 75% confluency. (DNA 
= deoxyribonucleic acid; FACS = fluorescence-activated cell sorting; GFP = green 
fluorescent protein.) 
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Figure 7. Sanger sequencing results for HUES9 cell line. DNA was isolated from 
GFP+ HUES9 cells that were confirmed to have the addition of the custom CRISPR-Cas9 
construct aimed at inducing the FADS2 mutation. Sequencing results show that 51.3% of 
sequenced colonies had a heterozygous indel, 41.0% had a homozygous indel, and 7.7% 
had no indel. None of the sequencing results returned data confirming the presence of the 
intended C → T mutation in the FADS2 promoter region. N = 39. (Cas9 = CRISPR-
associated protein 9; CRISPR = clustered regularly interspaced short palindromic repeat; 
DNA = deoxyribonucleic acid; FADS2 = fatty acid desaturase 2; GFP = green fluorescent  
protein; indel = insertion or deletion.) 
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Figure 8. Immunofluorescence imaging of definitive endoderm. Photomicrograph 
shows the expression levels of Sox17, Oct4, and Dapi (measure of DNA in cells). Oct4 is 
a pluripotency marker which should be lowly expressed at the definitive endoderm stage. 
Sox17 is upregulated in definitive endoderm. A combination of low Oct4 and high 
Sox17, as shown, indicates good definitive endoderm efficiency. Image captured at 10x 
magnification. (Dapi = 4,6-diamidino-2-phenylindole; DNA = deoxyribonucleic acid; 
Oct4 = octamer-binding transcription factor 4; Sox17 = SRY (sex determining region Y)-
box 17.) 
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Figure 9. Immunofluorescence imaging of anterior foregut endoderm. 
Photomicrograph shows the expression levels of Sox2, FoxA2, and Dapi (measure of 
DNA in cells). Cells that are double-positive for Sox2 and FoxA2 indicate good anterior 
foregut endoderm efficiency as seen in the upper right quadrant. Image captured at 20x 
magnification. (Dapi = 4,6-diamidino-2-phenylindole; DNA = deoxyribonucleic acid; 
FoxA2 = forkhead box A2; Sox2 = SRY (sex determining region Y)-box 2.)  
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